Roblox Stock Hit by Wave of Analyst Downgrades After Weak Guidance
Monetization slows, visibility drops, and price targets are cut.
Already have an account? Sign in.
Monetization slows, visibility drops, and price targets are cut.
Neurocrine reported $959M Q2 revenue (+39%) and raised Ingrezza guidance. Stock fell on short-term concerns, but analysts call the dip overdone and raise targets.
4D Molecular’s gene therapy could reduce eye injections for AMD patients. B. Riley sees major upside if Phase 3 results succeed. 4D-150 gene therapy fully funded to H2 2028.
Novo Nordisk’s ziltivekimab failed to reduce major cardiovascular events in the late-stage ZEUS trial of high-risk patients.